Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy

15 Oct 2020

Abstract excerpt

BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder and is one of the most common muscular dystrophies. There are currently few effective therapies to treat the disease, although many small-molecule approaches are being pursued. Certain histone deacetylase inhibitors (HDACi) have been shown to ameliorate DMD phenotypes in mouse and zebrafish animal models. The HDACi givinostat has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Neurogenetic and Muscular Disorders Research
Share to Zebrafish Biomedical Research Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33059738
DOI: 10.1186/s13395-020-00251-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophyPMID 33059738Read ↗

A novel drug-combination screen in zebrafish identifies epigenetic small molecule candidates for Duchenne muscular dystrophySemantic proximity Read ↗

Epigenetic small molecule screening identifies a new HDACi compound for ameliorating Duchenne muscular dystrophySemantic proximity Read ↗

Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy.Semantic proximity Read ↗

Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophySemantic proximity Read ↗

Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.Semantic proximity Read ↗

Drug screening in a zebrafish model of Duchenne muscular dystrophy.Semantic proximity Read ↗

Dystrophic muscle improvement in zebrafish via increased heme oxygenase signalingSemantic proximity Read ↗

Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic DiseasesSemantic proximity Read ↗

Recent advances using zebrafish animal models for muscle disease drug discoverySemantic proximity Read ↗

HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patientsSemantic proximity Read ↗

Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine.Semantic proximity Read ↗

Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular DystrophiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.